Document resource
Obesity drugs such as semaglutide (Wegovy) and tirzepatide (Mounjaro) produce substantial weight loss for patients but do not meaningfully improve their quality of life, and most do not show cardiovascular benefits at one year, shows a meta-analysis of latest trial data published in The BMJ.1